Drug Profile

CUV 9900

Alternative Names: CUV-9900

Latest Information Update: 12 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Arizona
Class Melanocortins; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies
Mechanism of Action Melanocortin type 1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 May 2023 Preclinical development in Skin disorders is ongoing in Australia (Clinuvel Pharmaceuticals pipeline, May 2023)
28 Aug 2021 No recent reports of development identified for preclinical development in Skin-disorders in Australia
22 Aug 2019 Preclinical development in Skin disorders is ongoing in Australia (Clinuvel Pharmaceuticals website, August 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com